Healthcare Industry News: vascular access
News Release - September 5, 2007
NovoSci Receives FDA Clearance for Hemodialysis CathetersNovoSci Enters The vascular access Market
THE WOODLANDS, Texas--(HSMN NewsFeed)--NovoSci (the Company) today announced that it has received FDA clearance to market its new D-Line brand of dual lumen, short-term hemodialysis catheters. The D-Line catheters have been successfully marketed in Europe, South American and Asia for a number of years and are now available in the US. They are first in a series of new product acquisitions for the Company and part of its strategy to expand its offering of single-use, disposable medical products.
"The addition of the D-Line Hemodialysis catheters to our product portfolio represents an important step for NovoSci," said CEO 'Mike' Sorna. "It is part of our strategy to leverage our core capability as a manufacturer of single-use, disposable medical products, and our corporate knowledge base, to expand our sales to new markets, including vascular access."
Hemodialysis is a medical procedure used to treat patients with end stage renal disease (ESRD). The procedure entails the routing of a patient's blood through a machine to filter out waste products that would normally be removed by a functional kidney.
The D-Line hemodialysis catheters are used to access the patient's vein and to route the blood to the machine. The D-Line catheters are made from polyurethane that resists kinks, making them easier for the clinician to use. In addition, they have a smaller bore to enhance patient comfort.
The U.S. has one of the highest incidence rates of ESRD in the world and the largest population of ESRD patients. Over 400,000 Americans suffer from ESRD and require either kidney dialysis or transplantation to live. The increasing over-65 population in the U.S. is expected to expand the number of people susceptible to ESRD.
NovoSci develops, manufactures and markets high quality, single-use disposable medical products. Focused primarily in the cardiovascular, endovascular and nephrology treatment areas, these products enable physicians and clinicians to treat patients safely and effectively. The Company's manufacturing, warehousing and distribution services are housed in a 77,000 square foot facility in The Woodlands, TX. NovoSci also owns and operates a sterilization facility in nearby Conroe, TX. For more information please call 800-854-0567 or visit www.novosci.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.